DALLAS, Texas, Oct. 29 -- The University of Texas Southwestern Medical Center posted the following news release: * * * Artificial intelligence-enabled triage tools may reflect human biases * UTSW study exposes weak points of large language models used to prioritize patients in the emergency department DALLAS - Oct. 20, 2026 - Artificial intelligence (AI)-driven tools used in emergency triage may be susceptible to the same clinical stigmas associated with human assessments, researchers at UT Southwestern Medical Center reported in a study p more PR

WASHINGTON, Oct. 25 -- In response to a federal agency request for information, the following public comment letter was submitted electronically to the regulations.gov site. 200 Massachusetts Avenue, NW Suite 310 Washington, DC 20001 202.872.5500 www.bsa.org October 19, 2026 Regulatory Secretariat Division (MVCB) General Services Administration 1800 F Street NW, 2nd Floor Washington, DC 20405 Re: BSA Comments on the Revolutionary FAR Overhaul, Round 2 (FAR Cases 2026-003, 2026-006, and 2026-011)1 Dear Members of the FAR Council: The B more ST

BOSTON, Massachusetts, Oct. 24 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release: * * * Immunotherapy combo extends survival for patients with aggressive small cell lung cancer, based on trial results presented by Dana-Farber at ESMO Congress 2026 * Results suggest that introducing tarlatamab, a bispecific T-cell engager, earlier in treatment could meaningfully extend survival for a broader group of patients In patients with extensive-stage small cell lung cancer (ES-SCLC), tarlatamab, a bispecif more PR

WASHINGTON, Oct. 25 -- In response to a federal agency request for information, the following public comment letter was submitted electronically to the regulations.gov site. 700 Technology Square, 5th Floor Cambridge, MA 02139 617.674.5100 | massbio.org October 16, 2026 Dockets Management Staff (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Reauthorization of the Prescription Drug User Fee Act (PDUFA VIII), FY 2028-2032 (Docket No. FDA-2026-N-8163) To whom it may concern: The Massachusetts  more ST

BOSTON, Massachusetts, Oct. 24 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release: * * * Perioperative apalutamide in high-risk localized or locally advanced prostate cancer substudy supports reduced risk of metastasis and death * New analysis provides additional evidence on how the PROTEUS regimen compares with standard of care. An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer with apalutamide -- a next-generation neoadjuv more PR